RUES2
RUESe002-A
General#
Donor Information#
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46XY
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA104387770 |
Ethics#
| Was the embryo established purely for research purposes? | No |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Clinical Research and Development Services Corp. |
| Approval number | 03-06-01 |
hESC Derivation#
| Date of derivation | 2005-08-30 |
| Embryo stage | Blastula with ICM and Trophoblast |
| Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
| PGD Embryo? |
No |
| Expansion status |
3
|
| ICM morphology |
A
|
| Trophectoderm morphology |
a
|
| ZP removal technique | Enzymatic |
| Cell isolation | Immunosurgery |
| Cell seeding | Isolated ICM |
| Derived under xeno-free conditions? |
No |
| Derivation under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Feeders, matrigel/geltrex, laminin521 |
| Feeder cells |
CF1 PMEF |
| Passage method | Mechanically |
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
derivation and in vitro and in vivo characterization
Method documentation
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Login to share your feedback, experiences or results with the research community.